<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03760120</url>
  </required_header>
  <id_info>
    <org_study_id>2291</org_study_id>
    <nct_id>NCT03760120</nct_id>
  </id_info>
  <brief_title>Short-term Effects of Physiotherapy on LCI</brief_title>
  <acronym>SPICy</acronym>
  <official_title>Short-term Effects of Positive Expiratory Pressure Mask on Ventilation Inhomogeneity in Children and Adolescents With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although some studies have brought some evidences about the efficacy of positive expiratory
      pressure (PEP)-mask therapy as an airway clearance technique, yet it is not clearly
      understood what is the contribution of this technique in modifying peripheral ventilation
      inhomogeneity, a typical feature of patients with Cystic Fibrosis (CF).

      The aim of this study is to investigate how PEP-MASK affects ventilation inhomogeneity in
      children and adolescents, with moderate to normal CF lung disease by the change in acinar
      airways (Sacin), lung clearance index (LCI) and conductive airways (Scond) indexes derived
      from nitrogen multiple-breath washout test (N2MBW).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigational device: PEP-MASK=Positive Expiratory Pressure delivered through a face mask.

      Standard Operating Procedures used for evaluating CF lung disease and ventilation
      inhomogeneity.

      Sample size: Based on preliminary data collected on seven subjects who performed nitrogen
      multiple-breath washout test before and after PEP-MASK, assuming a variation of 20% of Sacin,
      the study requires a sample size of 18 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Cross-over randomized controlled trial. Procedure: two nitrogen multiple-breath washout tests, one before and one after the intervention with PEP-Mask, either standard or sham allocation, during two subsequent mornings.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Technicians performing multiple-breath washout tests are blinded to treatment allocation; physiotherapists performing the treatment are blinded to multiple breath washout results; patients are blinded to the purpose of the study; the statistician will be blind to treatment allocation together with outcome assessors.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of PEP-MASK on ventilation heterogeneity (Sacin)</measure>
    <time_frame>Right after intervention/sham procedure</time_frame>
    <description>Acinar airways (Sacin) mean difference between treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of PEP-MASK on ventilation heterogeneity (Scond)</measure>
    <time_frame>Right after intervention/sham procedure</time_frame>
    <description>Conductive airways (Scond) mean difference between treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of PEP-MASK on ventilation heterogeneity (LCI)</measure>
    <time_frame>Right after intervention/sham procedure</time_frame>
    <description>Ventilation heterogeneity (LCI) mean difference between treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum weight</measure>
    <time_frame>From the beginning to the end of each intervention/sham procedure</time_frame>
    <description>Sputum weight (grams) will be collected throughout the active or sham interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>From the beginning to the end of each intervention/sham procedure</time_frame>
    <description>Oxygen saturation (SpO2) will be monitored throughout the active or sham interventions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>PEP standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEP sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PEP-MASK</intervention_name>
    <arm_group_label>PEP sham</arm_group_label>
    <arm_group_label>PEP standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CF diagnosis

          -  Patients hospitalized for a scheduled intravenous antibiotics cycle and regularly
             followed-up by the CF Centre

          -  ≥ 15 kilograms

          -  FEV1 ≥ 40%predicted

          -  Ability to perform NMBW test

          -  Ability to perform spirometry

          -  Willing to adhere to protocol procedures

          -  Patients in treatment with PEP-MASK

        Exclusion Criteria:

          -  Pulmonary Exacerbation within two last week

          -  Burkholderia cepacia infection

          -  Patients in lung transplantation waiting list

          -  Patients undergoing non invasive mechanical ventilation or oxygen therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Colombo</last_name>
    <role>Study Director</role>
    <affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Gambazza</last_name>
    <email>simone.gambazza@policlinico.mi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Ferrari</last_name>
    </contact>
    <investigator>
      <last_name>Beatrice Ferrari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Regionale di Riferimento Fibrosi Cistica</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Gambazza</last_name>
      <email>simone.gambazza@policlinico.mi.it</email>
    </contact>
    <investigator>
      <last_name>Simone Gambazza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.mbwtraining.com/ECFS_MBW_SOP.pdf</url>
    <description>Standard Operating Procedures LCI</description>
  </link>
  <reference>
    <citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38.</citation>
    <PMID>16055882</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>physiotherapy</keyword>
  <keyword>pulmonary function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

